Pages that link to "Q30799658"
Jump to navigation
Jump to search
The following pages link to Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry (Q30799658):
Displaying 50 items.
- Authorship bias in violence risk assessment? A systematic review and meta-analysis (Q21132537) (← links)
- A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists (Q21144620) (← links)
- Reporting bias in medical research - a narrative review (Q21203744) (← links)
- Effectiveness of second generation antipsychotics: a systematic review of randomized trials (Q21260262) (← links)
- Paroxetine versus other anti-depressive agents for depression (Q24197507) (← links)
- Bupropion versus other antidepressive agents for depression (Q24198214) (← links)
- Duloxetine versus other anti-depressive agents for depression (Q24198808) (← links)
- Citalopram versus other anti-depressive agents for depression (Q24202141) (← links)
- Industry sponsorship and research outcome (Q24202591) (← links)
- Mirtazapine versus other antidepressive agents for depression (Q24234046) (← links)
- Sertraline versus other antidepressive agents for depression (Q24235928) (← links)
- Fluvoxamine versus other anti-depressive agents for depression (Q24236814) (← links)
- Milnacipran versus other antidepressive agents for depression (Q24240125) (← links)
- Reboxetine versus other antidepressive agents for depression (Q24240504) (← links)
- Sertraline versus other antidepressive agents for depression (Q24241023) (← links)
- Escitalopram versus other antidepressive agents for depression (Q24241065) (← links)
- Sertraline versus other antidepressive agents for depression (Q24241157) (← links)
- Citalopram versus other anti-depressive agents for depression (Q24245653) (← links)
- Mirtazapine versus other anti-depressive agents for depression (Q24245696) (← links)
- Venlafaxine versus other anti-depressive agents for depression (Q24245701) (← links)
- Duloxetine versus other anti-depressive agents for depression (Q24245784) (← links)
- Fluvoxamine versus other anti-depressive agents for depression (Q24245886) (← links)
- Escitalopram versus other anti-depressive agents for depression (Q24245921) (← links)
- Milnacipran versus other anti-depressive agents for depression (Q24246033) (← links)
- Paroxetine versus other anti-depressive agents for depression (Q24246040) (← links)
- Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials (Q24632255) (← links)
- Who should sponsor sleep disorders pharmaceutical trials? (Q24641841) (← links)
- Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder (Q24643545) (← links)
- The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? (Q24650519) (← links)
- Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency (Q24658631) (← links)
- Do the CONSORT and STRICTA Checklists Improve the Reporting Quality of Acupuncture and Moxibustion Randomized Controlled Trials Published in Chinese Journals? A Systematic Review and Analysis of Trends (Q26774822) (← links)
- Beyond the 'new cross-cultural psychiatry': cultural biology, discursive psychology and the ironies of globalization (Q28238095) (← links)
- Do "Brain-Training" Programs Work? (Q28279012) (← links)
- Should the use of selective serotonin reuptake inhibitors in child and adolescent depression be banned? (Q28279067) (← links)
- SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials (Q28710019) (← links)
- How evidence-based medicine is failing due to biased trials and selective publication. (Q30362457) (← links)
- Financial, nonfinancial and editors' conflicts of interest in high-impact biomedical journals. (Q30486067) (← links)
- Use of large data sets and the future of personalized treatment (Q30870491) (← links)
- Soft targets: nurses and the pharmaceutical industry (Q33318540) (← links)
- Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents (Q33332138) (← links)
- Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis (Q33444727) (← links)
- Variability in conflict of interest disclosures by physicians presenting trauma research (Q33577335) (← links)
- Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of a large impact on general practitioners' confidence in conclusions, a three-arm randomized controlled trial (Q33617087) (← links)
- Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research. (Q33807895) (← links)
- Dealing with publication bias in translational stroke research (Q33815012) (← links)
- Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness (Q33938276) (← links)
- Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications (Q34025773) (← links)
- Conflict of interest in spine research reporting (Q34406597) (← links)
- A systematic appraisal of allegiance effect in randomized controlled trials of psychotherapy (Q34494570) (← links)
- Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials (Q34578579) (← links)